InnoCare Pharma (09969) released its results for the first three quarters of 2026, reporting total operating revenue of RMB 2.099 billion, up 88.21% from the same period a year earlier.

Pharmaceutical sales revenue reached RMB 1.449 billion, an increase of 41.47% year on year.

The growth in operating revenue was mainly driven by continued volume expansion of the core product orelabrutinib, new sales contributions from tafasitamab and zurletrectinib, and the completion of subsequent milestone deliveries under the company's licensing agreement with Zenas BioPharma, Inc.

Net profit attributable to shareholders of the listed company was approximately RMB 656 million, marking a turnaround from a loss in the prior-year period.

From January to September 2026, the company's net cash flow from operating activities was RMB 220 million, turning positive from negative a year earlier, mainly benefiting from higher pharmaceutical sales and licensing revenue as the company's operating cash flow position continued to improve.